Adagio Medical Holdings posts Q3 net loss of $10.1 million

Reuters11-13

Adagio Medical Holdings posts Q3 net loss of $10.1 million

Adagio Medical Holdings Inc. reported a net loss of $10.1 million for the third quarter ended September 30, 2025, compared to a net loss of $4.6 million for the same period in 2024. Cost of revenue was $0.03 million, down from $0.6 million in the prior-year quarter. Research and development expenses rose to $2.8 million from $2.5 million, while selling, general and administrative expenses decreased to $2.9 million from $7.8 million. The company reported cash and cash equivalents of $4.7 million as of September 30, 2025. Recent business developments include the completion of a private placement with gross proceeds of up to $50 million, the completion of enrollment in the 209-patient FULCRUM-VT pivotal trial, and the appointment of Deborah Kaster as Chief Financial Officer in addition to her role as Chief Business Officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112929137) on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583588696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583588696","market":"us","top_or_hot":-1,"title":"Adagio Medical Holdings posts Q3 net loss of $10.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagio Medical Holdings posts Q3 net loss of $10.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagio Medical Holdings Inc. reported a net loss of $10.1 million for the third quarter ended September 30, 2025, compared to a net loss of $4.6 million for the same period in 2024. Cost of revenue was $0.03 million, down from $0.6 million in the prior-year quarter. Research and development expenses rose to $2.8 million from $2.5 million, while selling, general and administrative expenses decreased to $2.9 million from $7.8 million. The company reported cash and cash equivalents of $4.7 million as of September 30, 2025. Recent business developments include the completion of a private placement with gross proceeds of up to $50 million, the completion of enrollment in the 209-patient FULCRUM-VT pivotal trial, and the appointment of Deborah Kaster as Chief Financial Officer in addition to her role as Chief Business Officer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112929137) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Medical Holdings posts Q3 net loss of $10.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Medical Holdings posts Q3 net loss of $10.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagio Medical Holdings posts Q3 net loss of $10.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagio Medical Holdings Inc. reported a net loss of $10.1 million for the third quarter ended September 30, 2025, compared to a net loss of $4.6 million for the same period in 2024. Cost of revenue was $0.03 million, down from $0.6 million in the prior-year quarter. Research and development expenses rose to $2.8 million from $2.5 million, while selling, general and administrative expenses decreased to $2.9 million from $7.8 million. The company reported cash and cash equivalents of $4.7 million as of September 30, 2025. Recent business developments include the completion of a private placement with gross proceeds of up to $50 million, the completion of enrollment in the 209-patient FULCRUM-VT pivotal trial, and the appointment of Deborah Kaster as Chief Financial Officer in addition to her role as Chief Business Officer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112929137) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XTNT","symbol_name":"Xtant Medical Holdings Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL60fSlh:1","article_id":"2583588696","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583588696","pubTimestamp":1762981722,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adagio Medical Holdings Inc. reported a net loss of $10.1 million for the third quarter ended September 30, 2025, compared to a net loss of $4.6 million for the same period in 2024. Cost of revenue was $0.03 million, down from $0.6 million in the prior-year quarter. Research and development expenses rose to $2.8 million from $2.5 million, while selling, general and administrative expenses decreased to $2.9 million from $7.8 million. The company reported cash and cash equivalents of $4.7 million as of September 30, 2025. Recent business developments include the completion of a private placement with gross proceeds of up to $50 million, the completion of enrollment in the 209-patient FULCRUM-VT pivotal trial, and the appointment of Deborah Kaster as Chief Financial Officer in addition to her role as Chief Business Officer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XTNT":"Xtant Medical Holdings Inc","ADGM":"Adagio Medical Holdings, Inc.","BK4082":"医疗保健设备","BK4198":"医疗保健用品"},"translate_title":"Adagio Medical Holdings第三季度净亏损1010万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XTNT":0.9,"ADGM":0.9},"content_text":"Adagio Medical Holdings posts Q3 net loss of $10.1 million\n    \n\n        Adagio Medical Holdings Inc. reported a net loss of $10.1 million for the third quarter ended September 30, 2025, compared to a net loss of $4.6 million for the same period in 2024. Cost of revenue was $0.03 million, down from $0.6 million in the prior-year quarter. Research and development expenses rose to $2.8 million from $2.5 million, while selling, general and administrative expenses decreased to $2.9 million from $7.8 million. The company reported cash and cash equivalents of $4.7 million as of September 30, 2025. Recent business developments include the completion of a private placement with gross proceeds of up to $50 million, the completion of enrollment in the 209-patient FULCRUM-VT pivotal trial, and the appointment of Deborah Kaster as Chief Financial Officer in addition to her role as Chief Business Officer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251112929137) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583588696","isCrawlerRequest":true}